Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences

Rhea-AI Summary

Gracell Biotechnologies (NASDAQ: GRCL) announced its participation in several upcoming healthcare conferences. The events include the Goldman Sachs Asia Pacific Healthcare Forum (November 15-17, 2021), the BioCentury-BayHelix China Healthcare Summit (November 17, 2021), and the Jefferies London Healthcare Conference (November 18-19, 2021). Gracell aims to showcase its innovative cell therapies designed to treat cancer. The company utilizes its advanced FasTCAR and TruUCAR technology platforms to create effective and affordable solutions for patients.

SUZHOU, China and PALO ALTO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming conferences:

Goldman Sachs Asia Pacific Healthcare Forum 2021

One-on-one and small group meetings (virtual): November 15-17, 2021

For more information, please contact your Goldman Sachs representative.

8^th BioCentury-BayHelix China Healthcare Summit

In-person one-on-one and small group meetings (Shanghai, China): November 17, 2021

Panel - China Biotech CEO Blue Ribbon Roundtable: November 17, 2021, 14:30-15:15pm CST

For more information, please contact your Biocentury representative.

Jefferies London Healthcare Conference

One-on-one and small group meetings (virtual): November 18-19, 2021

Fireside Chat: available on-demand beginning on Thursday, November 18, 3:00am ET

Webcast link: https://ir.gracellbio.com/news-events/events-and-presentations

The replay of the fireside chat can be accessed through the “News and Events” section of the Gracell Investor website.

For more information, please contact your Jefferies representative.

20^th Morgan Stanley Annual Asia Pacific Summit

One-on-one and small group meetings (virtual): November 18-19, 2021

For more information, please contact your Morgan Stanley representative.

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com

Follow @GracellBio on LinkedIn

Media contact

Marvin Tang

marvin.tang@gracellbio.com

Investor contact

Gracie Tong

gracie.tong@gracellbio.com

 

FAQ

When will Gracell participate in the Goldman Sachs Asia Pacific Healthcare Forum?

Gracell will participate in the Goldman Sachs Asia Pacific Healthcare Forum from November 15-17, 2021.

What is the date for the BioCentury-BayHelix China Healthcare Summit where Gracell is participating?

The BioCentury-BayHelix China Healthcare Summit is scheduled for November 17, 2021.

What events will Gracell attend on November 18-19, 2021?

Gracell will attend the Jefferies London Healthcare Conference and the Morgan Stanley Annual Asia Pacific Summit on November 18-19, 2021.

What technology does Gracell use for developing cell therapies?

Gracell utilizes its FasTCAR and TruUCAR technology platforms to develop its cell therapies.

What is the focus of Gracell's research and development?

Gracell focuses on developing highly efficacious and affordable cell therapies for cancer treatment.